FDA approved studies are yielding transformative results for psychedelics as medicine to treat a wide range of mental and physical health conditions. Within the last couple of years, the prospect of cures for treatment-resistant diseases, such as major depression, PTSD, and addiction, is racing toward reality with a handful of pioneering companies and world class universities leading the charge.
The movement is creating tremendous promise for people suffering with these debilitating diseases and a deep sense of accomplishment for those who have long sought to include psychedelics in scientific consideration as a viable treatment modality.
While psychedelics are expected to heal tens of millions globally and transcend the way we think about the mind and human consciousness, it is also creating unprecedented investment opportunities with the first IPOs happening earlier this year, and jurisdictions around the country are moving to decriminalize use and possession.
Our News section will keep readers informed with all of the latest industry updates with regard to research progress, investor news and cultural reform.
TDR’s Top 5 Psychedelic Developments For The Week of June 29
Despite a strong rally in psychedelic stocks to close the week, industry leader Champignon Brands was a notable laggard.
The psychedelics renaissance is here as a colorful trip down the line awaits.
MAPS published new evidence to support MDMA-assisted psychotherapy’s lasting benefits for PTSD.
Community members deserve access to medicines that have been used for thousands of years and shouldn’t fear prosecution for safe and effective treatments.
Voters would likely approve a measure to decriminalize psychedelics in the nation’s capital if organizers qualified it for November ballot.
Heading into the second half of the year, industry experts and advocates are considering the current psychedelics outlook as the market continues to grow.
This session for clinicians gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy.